Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and young people older than 1 month and younger than 18 years of age
- People who have been newly diagnosed with a specific type of leukemia known as Philadelphia chromosome-positive or BCR::ABL1-positive B-cell acute lymphoblastic leukemia (B-ALL)
- People whose parent or legal guardian has provided written consent to participate, in line with local laws and regulations
Who may not be able to join:
- People whose leukemia developed from a prior condition called chronic myeloid leukemia (CML)
- People with a known inherited immune system disorder or inherited metabolic disease
- People with a heart condition present from birth that causes the heart to work poorly
- People with digestive system problems that could significantly affect how the body absorbs the study medication
- People with severe malnutrition, an active infection that is not under control, or serious heart or blood vessel disease
- People with a significant brain or nervous system condition, such as seizures that cannot be controlled or an autoimmune disease affecting the brain or nervous system
- People who have received steroid (glucocorticoid) treatment for 14 days or more, or a targeted therapy for more than 7 days, within the month before joining; or any chemotherapy, systemic cancer treatment (including targeted therapies), or radiation therapy within the 3 months before joining — with the exception of emergency radiation used to relieve airway blockage
- People with other significant health conditions or mental health disorders that could affect their safety, their ability to follow the study requirements, or the reliability of the study results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Phone: +86 22 23909196
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Day 48 end-of-induction measurable residual diseases (MRD48) after induction remission with olverembatinib and blinatumomab, compared to MRD46 of those treated with dasatinib plus chemotherapy induction (CCCG-ALL-2015 /2020) or from historical cohorts .
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.